Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| APTARGROUP, INC.ATR · Entity 165 | Director · President and CEO | August 03, 2026 | August 04, 2026 |
| Ingredion IncINGR · Entity 3745 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
APTARGROUP, INC.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 238,729 |
Ending reported balance
After 2026-08-03 transaction · row 3
2 source rows · reconciled sequenceRow 2 · 2026-08-03 · Exercise / conversion · Acquired 9,838 · Balance 248,567 Row 3 · 2026-08-03 · Sale · Disposed 9,838 · Balance 238,729 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.0000 to $136.5200 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $74.79 · Expires 2027-02-10 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-03 · Exercise / conversion · Disposed 9,838 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) trust | 3,150 |
Reported balance
Holding disclosure · report date 2026-08-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,150 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.0000 to $136.5200 inclusive. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth.
Ingredion Inc
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,797 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,797 · Balance 1,797 F1: These are restricted stock units ("RSUs") issued under the Ingredion Incorporated Stock Incentive Plan to the Company's outside directors as part of their annual retainer (as further described in Exhibit 10.26 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 17, 2026). One portion of this grant covers the period from April 1, 2026 to May 19, 2026, and the remaining portion represents the full value of the outside directors' 2026 annual equity retainer, reflecting the Company's shift in 2026 from a calendar-year basis for director stock compensation to a twelve-month cycle aligned with the annual stockholder meeting. The RSUs may be settled only in shares of common stock (one share per RSU) and will vest on May 19, 2027, subject to the Committee's discretion to accelerate vesting upon an outside director's retirement, death, disability, or a Change in Control. |
| Common StockSEC Table I · non-derivative | Indirectthrough The Tanda Joint Living Trust | 10,737 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,737 |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units ("RSUs") issued under the Ingredion Incorporated Stock Incentive Plan to the Company's outside directors as part of their annual retainer (as further described in Exhibit 10.26 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 17, 2026). One portion of this grant covers the period from April 1, 2026 to May 19, 2026, and the remaining portion represents the full value of the outside directors' 2026 annual equity retainer, reflecting the Company's shift in 2026 from a calendar-year basis for director stock compensation to a twelve-month cycle aligned with the annual stockholder meeting. The RSUs may be settled only in shares of common stock (one share per RSU) and will vest on May 19, 2027, subject to the Committee's discretion to accelerate vesting upon an outside director's retirement, death, disability, or a Change in Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Patheon N.V.
Report date August 29, 2017 · Filed August 30, 2017
Section 16 reporting ended · disclosed 2017-08-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Ordinary Shares)SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 1
1 source rowRow 1 · 2017-08-29 · Other · Disposed 4,659 · Balance 0 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4: This amount represents 4,659 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2)
F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3)
F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer.
F4: This amount represents 4,659 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2021 Filed Oct 5, 2021 18:49 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 359 | $90.48 | $32,482.32 |
DisclosureSEC source: 0001127602-21-026663 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,323 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 17:12 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 357 | $90.99 | $32,483.43 |
DisclosureSEC source: 0001127602-21-021519 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. F2 · balance_after: Includes shares of common stock acquired through dividend reinvestment. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 16:59 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 360 | $90.21 | $32,475.60 |
DisclosureSEC source: 0001127602-21-012936 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,607 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. F2 · balance_after: Includes shares of common stock acquired through dividend reinvestment. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 19:29 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 2,315 | $142.47 | $329,818.05 |
DisclosureSEC source: 0000896622-21-000021 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,509 Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:31 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 3,221 | $140.77 | $453,420.17 |
DisclosureSEC source: 0000905148-21-000333 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,824 Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 19:44 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 14,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000316 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,045 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:36 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 8,297 | $130.07 | $1,079,190.79 |
DisclosureSEC source: 0001140361-21-007035 · form4.xml · nonDerivative · entry 4 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,533 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:36 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 18,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-007035 · form4.xml · nonDerivative · entry 3 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,830 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:36 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 4,792 | $130.07 | $623,295.44 |
DisclosureSEC source: 0001140361-21-007035 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,102 Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:29 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 826 | $130.30 | $107,627.80 |
DisclosureSEC source: 0000905148-21-000264 · form4.xml · nonDerivative · entry 3 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,894 Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:29 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 2,909 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000264 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,720 Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:43 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 413 | $78.67 | $32,490.71 |
DisclosureSEC source: 0001127602-21-001120 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. F2 · balance_after: Includes shares of common stock acquired through dividend reinvestment. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:43 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 434 | $74.45 | $32,311.30 |
DisclosureSEC source: 0001127602-20-026542 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 23:17 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 400 | $81.14 | $32,456.00 |
DisclosureSEC source: 0001127602-20-021235 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,385 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. F2 · balance_after: Includes shares of common stock acquired through dividend reinvestment. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 18:58 UTC | Ingredion Inc INGR · Entity 3745 | GiftCommon Stock | 1,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018233 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · through The Tanda Joint Living Trust Disclosed balance after: 1,337 F1 · balance_after: On 5/29/20 the reporting person transferred 1,337 directly owned shares of Ingredion Incorporated common stock to The Tanda Joint Living Trust u/a/d/ 7/21/16 of which the insider and his spouse are the trustees and immediate family members are the beneficiaries. Read SEC document |
| May 29, 2020 Filed Jun 1, 2020 18:58 UTC | Ingredion Inc INGR · Entity 3745 | GiftCommon Stock | 1,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018233 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 985 Read SEC document |
| May 13, 2020 Filed May 13, 2020 22:35 UTC | Ingredion Inc INGR · Entity 3745 | PurchaseCommon Stock | 4 | $79.45 | $317.78 |
DisclosureSEC source: 0001127602-20-016483 · form4.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,322 Read SEC document |
| May 13, 2020 Filed May 13, 2020 22:35 UTC | Ingredion Inc INGR · Entity 3745 | PurchaseCommon Stock | 981 | $81.04 | $79,504.95 |
DisclosureSEC source: 0001127602-20-016483 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,318 Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 19:43 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 430 | $75.54 | $32,482.20 |
DisclosureSEC source: 0001127602-20-013050 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,337 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. F2 · balance_after: Includes shares of common stock acquired through dividend reinvestment. Read SEC document |
| March 26, 2020 Filed Mar 26, 2020 22:27 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 2,315 | $90.18 | $208,766.70 |
DisclosureSEC source: 0000896622-20-000012 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,811 Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:55 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 21,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-20-000010 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,126 Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 22:37 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 4,790 | $101.07 | $484,125.30 |
DisclosureSEC source: 0000896622-20-000008 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,315 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 15:58 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 5,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-20-000006 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,105 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 22:13 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 349 | $92.95 | $32,439.55 |
DisclosureSEC source: 0001127602-20-001197 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 21:43 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 371 | $80.65 | $29,921.15 |
DisclosureSEC source: 0001127602-19-030051 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558 F1 · shares: These are shares of common stock issued to the Company's outside Directors as part of their annual retainer. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 14:22 UTC | Ingredion Inc INGR · Entity 3745 | GrantCommon Stock | 187 | $76.65 | $14,333.55 |
DisclosureSEC source: 0001127602-19-027096 · form4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187 F1 · shares: These are shares of common stock issued to the Company's outside directors as part of their annual retainer. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 22:09 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 15,692 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-19-000006 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,532 Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 17:14 UTC | APTARGROUP, INC. ATR · Entity 165 | Tax withholdingCommon Stock | 3,091 | $101.73 | $314,447.43 |
DisclosureSEC source: 0000896622-19-000004 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,840 Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 23:31 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 11,496 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-19-000002 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,931 Read SEC document |
| May 11, 2018 Filed May 14, 2018 22:12 UTC | APTARGROUP, INC. ATR · Entity 165 | Exercise / conversionStock Option · Derivative | 12,500 | $0.00 Strike: $74.79 | $0.00 |
DisclosureSEC source: 0000896622-18-000015 · edgar.xml · derivative · entry 3 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,838 Underlying: Common Stock · 12,500 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2018 Filed May 14, 2018 22:12 UTC | APTARGROUP, INC. ATR · Entity 165 | Exercise / conversionCommon Stock | 12,500 | $74.79 | $934,875.00 |
DisclosureSEC source: 0000896622-18-000015 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 18:58 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantCommon Stock | 20,935 | $0.00 | $0.00 |
DisclosureSEC source: 0000896622-18-000007 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,935 Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 23:25 UTC | APTARGROUP, INC. ATR · Entity 165 | Exercise / conversionStock Option · Derivative | 14,000 | $0.00 Strike: $74.79 | $0.00 |
DisclosureSEC source: 0000896622-18-000005 · edgar.xml · derivative · entry 3 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,338 Underlying: Common Stock · 14,000 shares Expires 2027-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 14, 2018 23:25 UTC | APTARGROUP, INC. ATR · Entity 165 | Exercise / conversionCommon Stock | 14,000 | $74.79 | $1,047,060.00 |
DisclosureSEC source: 0000896622-18-000005 · edgar.xml · nonDerivative · entry 2 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2017 Filed Aug 30, 2017 19:04 UTC | Patheon N.V. PTHN · Entity 173467 | OtherRestricted Stock Units (Ordinary Shares) | 4,659 | $35.00 | $163,065.00 |
DisclosureSEC source: 0001209191-17-050810 · doc4.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · kind: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · kind: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4 · shares: This amount represents 4,659 restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit upon the closing of the tender offer. F1 · price: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was canceled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · price: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · price: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 13:35 UTC | Patheon N.V. PTHN · Entity 173467 | GrantRestricted Stock Units (Ordinary Shares) | 4,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001679516-17-000008 · wf-form4_149063609766121.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,659 F1 · shares: On March 23, 2017, the reporting person was granted restricted stock units which will vest in full on the one-year anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 20:44 UTC | APTARGROUP, INC. ATR · Entity 165 | PurchaseCommon Stock | 2,000 | $75.21 | $150,420.00 |
DisclosureSEC source: 0001679516-17-000006 · edgar.xml · nonDerivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Read SEC document |
| February 10, 2017 Filed Feb 13, 2017 22:16 UTC | APTARGROUP, INC. ATR · Entity 165 | GrantStock Option · Derivative | 160,338 | $0.00 Strike: $74.79 | $0.00 |
DisclosureSEC source: 0001679516-17-000004 · edgar.xml · derivative · entry 1 Tanda Stephan B. · CIK 0001679516 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,338 Underlying: Common Stock · 160,338 shares Expires 2027-02-10 F1 · derivative.exercise_date: The option vests in three equal installments beginning on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.